Estrella Immunopharma, Inc. ESLA
0.42 USD -0.01 (-1.95%)
At closeNov 3, 2026, 7:44 PM EST
0.42 0.00 0.00%
After hours · Nov 3, 7:44 PM ET
0.3517 Day range 0.475
0.314 52-week range 3.05
- YTD
- -73.21%
- 1 year
- -86.30%
Financial health
Altman Z-Score
-52.49 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 2
- Return on Equity 5
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 1
Valuation
P/E -4.5×
FY 2020 5y median -5.2× FY 2025
P/S 0.0×
FY 2020 5y median 0.0× FY 2025
P/B -5.5×
FY 2020 5y median 9.1× FY 2025
P/FCF -32.2×
FY 2020 5y median -32.2× FY 2025
EV/EBITDA -4.3×
FY 2020 5y median -4.9× FY 2025
EV/Sales 0.0×
FY 2020 5y median 0.0× FY 2025
FCF Yield -3.1%
FY 2020 5y median -3.1% FY 2025
Profitability
Gross Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2020 5y median 0.0% FY 2025
ROE 126.0%
FY 2020 5y median -157.2% FY 2025
ROIC 126.0%
FY 2020 5y median -51.5% FY 2025
ROA -411.2%
FY 2020 5y median -164.2% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2020 FY 2025
Operating Income -47.7%
FY 2020 FY 2025
EPS (diluted) -45.8%
FY 2020 FY 2025
Free Cash Flow 42.6%
FY 2020 FY 2025
Financial Health
Current Ratio 0.1×
FY 2020 5y median 0.5× FY 2025
Quick Ratio 0.1×
FY 2020 5y median 0.5× FY 2025
Debt / Equity 0.0×
FY 2020 5y median 0.0× FY 2025
Net Debt / EBITDA 0.1×
FY 2020 5y median 0.1× FY 2025
Interest Coverage 0.0×
FY 2020 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2020 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2020 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31